GIUGLIANO, FEDERICA

GIUGLIANO, FEDERICA  

Universita' degli Studi di MILANO  

Mostra records
Risultati 1 - 20 di 22 (tempo di esecuzione: 0.007 secondi).
Titolo Data di pubblicazione Autori Tipo File Abstract
A set of easy and stringent criteria to identify immune-related adverse events (IrAE Scoring System, ISS) improves correlation with outcome in a phase 1-2 trial population 2022 Mazzarella, LGiugliano, FNicolo', ECrimini, EUliano, JCorti, CRepetto, MAntonarelli, GAscione, LVivanet, GCriscitiello, CCurigliano, G + Article (author) -
Antibody–drug conjugates for the treatment of breast cancer 2021 Corti C.Giugliano F.Curigliano G. + Article (author) -
Auto-immune toxiity of Sars-Cov2 vaccine in patients with thymic epithelial tumours: a prospective analysis from the tyme net 2021 Giugliano FCorti CCurigliano G + Article (author) -
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents 2023 Tarantino, PaoloAntonarelli, GabrieleBoscolo Bielo, LucaCrimini, EdoardoGiugliano, FedericaZagami, PaolaCorti, ChiaraTrapani, DarioCriscitiello, CarmenCurigliano, Giuseppe + Article (author) -
Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents 2022 Tarantino, PaoloAntonarelli, GabrieleBoscolo Bielo, LucaMarra, AntonioCrimini, EdoardoGiugliano, FedericaZagami, PaolaCorti, ChiaraTrapani, DarioMorganti, StefaniaCriscitiello, CarmenCurigliano, Giuseppe + Article (author) -
Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer : a systematic review 2021 Trapani, DGiugliano, FUliano, JFerraro, ECriscitiello, CCurigliano, G + Article (author) -
Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management 2023 Francesca Maria PortaFederica GiuglianoChiara FrascarelliElham SajjadiKonstantinos VenetisElena Guerini-RoccoGiuseppe CuriglianoCarmen CriscitielloNicola Fusco + Article (author) -
Bystander effect of antibody-drug conjugates: fact or fiction? 2022 Giugliano, FedericaCorti, ChiaraTarantino, PaoloMichelini, FlaviaCurigliano, Giuseppe Article (author) -
Characterization of low HER2 expressions in de-novo metastatic breast cancer 2021 Tarantino, PZagami, PGiugliano, FCrimini, ECorti, CUliano, JMorganti, SCriscitiello, CCurigliano, G + Article (author) -
Clinical development and current role of margetuximab for the treatment of breast cancer 2021 Uliano J.Morganti S.Giugliano F.Crimini E.Curigliano G. + Article (author) -
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives 2022 Giugliano, FedericaAscione, LilianaTarantino, PaoloCorti, ChiaraCurigliano, Giuseppe + Article (author) -
Evolution of low HER2 expression between early and advanced-stage breast cancer 2022 Giugliano F.Zagami P.Vivanet G.Bellerba F.Trapani D.Criscitiello C.Curigliano G. + Article (author) -
First line treatment of BRAF mutated advanced melanoma: Does one size fit all? 2021 Giugliano, FedericaCrimini, EdoardoZagami, PaolaUliano, JacopoCorti, ChiaraTrapani, DarioCurigliano, Giuseppe + Article (author) -
Harmonizing PD-L1 testing in metastatic triple negative breast cancer 2022 Giugliano F.Antonarelli G.Curigliano G. + Article (author) -
HER2-Low Breast Cancer: a New Subtype? 2023 Corti, ChiaraGiugliano, FedericaTarantino, PaoloCriscitiello, CarmenCurigliano, Giuseppe + Article (author) -
Immune-related adverse events are correlated with significantly improved outcome in a phase I trial population exposed to combination immunotherapy 2021 Giugliano, FCrimini, EUliano, JCorti, CRepetto, MAntonarelli, GVivanet, GCriscitiello, CCurigliano, G + Article (author) -
Margetuximab for the treatment of HER2-positive metastatic breast cancer 2021 Morganti S.Uliano J.Giugliano F.Crimini E.Curigliano G. + Article (author) -
Research and clinical landscape of bispecific antibodies for the treatment of solid malignancies 2021 Antonarelli G.Giugliano F.Corti C.Repetto M.Curigliano G. + Article (author) -
SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis 2022 Giugliano, FedericaGalli, GiuliaCorti, ChiaraUliano, JacopoVivanet, GraziaCurigliano, GiuseppeConforti, Fabio + Article (author) -
Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions 2021 Repetto M.Crimini E.Giugliano F.Morganti S.Curigliano G. + Article (author) -